BioCryst says Japan approves Orladeyo for pediatric HAE patients aged 2-11

• BioCryst won Japanese MHLW marketing clearance for once-daily Orladeyo to prevent hereditary angioedema attacks in children aged 2 to <12.
• Approval broadens Japan access to the first oral prophylactic option for this age group; launch follows National Health Insurance pricing.
• OrphanPacific holds the Japan marketing authorization.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. BioCryst Pharmaceuticals Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202608250701PRIMZONEFULLFEED9815310) on August 25, 2026, and is solely responsible for the information contained therein.